0001209191-18-010536.txt : 20180215 0001209191-18-010536.hdr.sgml : 20180215 20180215193132 ACCESSION NUMBER: 0001209191-18-010536 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180212 FILED AS OF DATE: 20180215 DATE AS OF CHANGE: 20180215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Azelby Robert CENTRAL INDEX KEY: 0001656998 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 18619282 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVE. NORTH, STE 300 CITY: SEATTLE STATE: WA ZIP: 98109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2065821600 MAIL ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2018-02-12 2018-02-14 0 0001594864 Juno Therapeutics, Inc. JUNO 0001656998 Azelby Robert C/O 400 DEXTER AVENUE NORTH SUITE 1200 SEATTLE WA 98109 0 1 0 0 EVP & Chief Commercial Officer Common Stock 2018-02-12 4 S 0 4159 85.55 D 89612 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2017. This Amendment to Form 4 is filed solely for the purpose of correcting a clerical error in the number of shares sold, as reported on the Form 4 filed February 14, 2018. /s/ Zachary D. Hale, attorney-in-fact 2018-02-15